Overgaard, Rune V.
Novo Nordisk (Denmark)
4 papers on CoChatORCID 0000-0001-7095-4270
Most cited papers
- Verified
Exposure-response analyses of liraglutide 3.0 mg for weight management
Wilding, J. P. H., Overgaard, R. V., Jacobsen, L. V., Jensen, C. B., & le Roux, C. W. (2016) · Diabetes, Obesity and Metabolism
Pharmacology and Obesity TreatmentDiabetes Treatment and Management
Cited by 102
- Verified
Liraglutide 3.0 mg for Weight Management: A Population Pharmacokinetic Analysis
Overgaard, R. V., Petri, K. C., Jacobsen, L. V., & Jensen, C. B. (2016) · Clinical Pharmacokinetics
Pharmacology and Obesity TreatmentPharmaceutical studies and practices
Cited by 64
- Verified
Exposure-response analysis for evaluation of semaglutide dose levels in type 2 diabetes
Petri, K. C. C., Ingwersen, S. H., Flint, A., Zacho, J., & Overgaard, R. V. (2018) · Diabetes, Obesity and Metabolism
Diabetes Treatment and ManagementDiabetes Management and Research
Cited by 53
- Verified
Impact of dose‐escalation schemes and drug discontinuation on weight loss outcomes with liraglutide 3.0 mg: A model‐based approach
Papathanasiou, T., Strathe, A., Agersø, H., Lund, T. M., & Overgaard, R. V. (2020) · Diabetes, Obesity and Metabolism
Pharmacology and Obesity TreatmentDiabetes Treatment and Management
Cited by 18
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free